Europe Infertility Drugs Market Size & Outlook, 2023-2030
Europe infertility drugs market, 2018-2030 (US$M)
Related Markets
Europe infertility drugs market highlights
- The Europe infertility drugs market generated a revenue of USD 1,400.8 million in 2023.
- The market is expected to grow at a CAGR of 6.4% from 2024 to 2030.
- In terms of segment, gonadotrophins was the largest revenue generating drug class in 2023.
- Gonadotrophins is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 1,400.8 million |
| Market revenue in 2030 | USD 2,165.3 million |
| Growth rate | 6.4% (CAGR from 2023 to 2030) |
| Largest segment | Gonadotrophins |
| Fastest growing segment | Gonadotrophins |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gonadotrophins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists |
| Key market players worldwide | Merck & Co Inc, Organon & Co Ordinary Shares, Abbott Laboratories, Novartis AG ADR, Bayer AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd ADR, Sanofi SA, Mankind Pharma, Ferring |
Other key industry trends
- In terms of revenue, Europe region accounted for 38.1% of the global infertility drugs market in 2023.
- Globally, Europe is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,399.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Infertility Drugs Market Scope
Infertility Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe infertility drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to infertility drugs market will help companies and investors design strategic landscapes.
Gonadotrophins was the largest segment with a revenue share of 54.38% in 2023. Horizon Databook has segmented the Europe infertility drugs market based on gonadotrophins, aromatase inhibitors, selective estrogen receptor modulators (serms), dopamine agonists covering the revenue growth of each sub-segment from 2018 to 2030.
- Europe Infertility Drugs Drug Class Outlook (Revenue, USD Million, 2018-2030)
- Gonadotrophins
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Dopamine Agonists
- Others
- Europe Infertility Drugs End Use Outlook (Revenue, USD Million, 2018-2030)
- Women
- Men
- Europe Infertility Drugs Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacy
- Specialty & Retail Pharmacy
- Others
Reasons to subscribe to Europe infertility drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe infertility drugs market databook
-
Our clientele includes a mix of infertility drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe infertility drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Europe infertility drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe infertility drugs market size, by country, 2018-2030 (US$M)
Europe Infertility Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
